Drug Profile
Montelukast oral film - IntelGenx
Alternative Names: INT 0043/2015; INT0043; Montelukast VersaFilm®Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator IntelGenx Corp.
- Class Acetates; Anti-inflammatories; Antiasthmatics; Antidementias; Bronchodilators; Neuroprotectants; Nootropics; Quinolines; Small molecules
- Mechanism of Action Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Alzheimer's disease; Parkinson's disease
- No development reported Mild cognitive impairment
Most Recent Events
- 08 Apr 2024 Phase-II clinical trials in Parkinson's disease (Adjunctive treatment) in Sweden (PO)
- 03 Apr 2024 IntelGenx completes the phase-IIa BUENA trial for Alzheimer's disease in Canada (PO) (NCT03402503)
- 14 Nov 2023 IntelGenx plans a phase II MONTPARK clinical trial for Parkinson’s Disease in Q1 of 2024